Affiliation:
1. Russian Children’s Clinical Hospital of Russian National Research Medical University n. a. N. I. Pirogov; Russian National Research Medical University n. a. N. I. Pirogov
2. Russian Children’s Clinical Hospital of Russian National Research Medical University n. a. N. I. Pirogov; Peoples’ Friendship University of Russia
3. Russian National Research Medical University n. a. N. I. Pirogov
Abstract
Drug interactions are a critical problem in clinical pharmacology and daily clinical practice. Physicians often face the need to prescribe a combination of two or more drugs (polypharmacy), especially when treating patients with several comorbidities. In some combinations, drugs, being chemically active substances, can enter into multi-drug interactions often with clinically significant adverse effects and/or reduction of therapy effectiveness, increasing the cost of treatment. Potential multi-drug interaction refers to the possibility of changing the pharmacological effect of one or more drugs when they are prescribed simultaneously or sequentially. Depending on the final result, the interaction may be synergistic (with increasing effect) or antagonistic (weakening or blockage of the effect).
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference33 articles.
1. Clinical Recommendations of the Ministry of Health of the Russian Federation. Cystic fibrosis (cystic fibrosis). 2021. (Electronic resource) https://cr.minzdrav.gov.ru/recomend/372_2 (circulation date 06.11.2022).
2. Lepakhin V. K., Kazakov A. S., Astakhova A. V., Pharmacoepidemiological study of adverse reactions associated with drug interactions. Clinical Pharmacology and Therapy. 2013, 22 (4), p. 92–96.
3. Golchin N., Johnson H., Bakaki P. M., Dawson N., Knight E. M.P, Meropol S. B., Liu R., Feinstein J. A., Bolen SD, Kleinman L. C., Horace A. Outcome measures in pediatric polypharmacy research: a scoping review. Drugs Ther Perspect. 2019 Sep; 35 (9): 447–458. DOI: 10.1007/s40267–019–00650–8. Epub 2019 Jul 12. PMID: 32256042; PMCID: PMC 7123381.
4. Endsley S. Deprescribing Unnecessary Medications: A Four-Part Process. Fam Pract Manag. 2018 May/Jun; 25 (3): 28–32. PMID: 29989773.
5. Dai D., Feinstein J. A., Morrison W., Zuppa A. F., Feudtner C. Epidemiology of Polypharmacy and Potential Drug-Drug Interactions Among Pediatric Patients in ICUs of U. S. Children’s Hospitals. Pediatr Crit Care Med. 2016 May; 17 (5): e218–28. DOI: 10.1097/PCC.0000000000000684. PMID: 26959349; PMCID: PMC 5243142.